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Abstract: Background and aims: Chronic hepatitis C is a global health 
problem with an estimated 170 million HCV infected individuals at risk of 
progressive liver disease and hepatocellular carcinoma (HCC). Autotaxin 
(ATX) is a phospholipase with diverse roles in physiological and 
pathological processes including inflammation and oncogenesis. Clinical 
studies have reported increased ATX expression in chronic hepatitis C, 
however, the pathways regulating ATX and its role in the viral life cycle 
are not well understood. Methods: In vitro hepatocyte and ex vivo liver 
culture systems along with chimeric humanized liver mice and HCC tissue 
enabled us to assess the interplay between ATX and the HCV life cycle. 
Results: HCV infection increased hepatocellular ATX RNA and protein 
expression. HCV infection stabilizes hypoxia inducible factors (HIFs) and 
we investigated a role for these transcription factors to regulate ATX. 
In vitro studies show that low oxygen increases hepatocellular ATX 
expression and transcriptome analysis showed a positive correlation 
between ATX mRNA levels and hypoxia gene score in HCC tumor tissue 
associated with HCV and other aetiologies. Importantly, inhibiting ATX-
lysophosphatidic acid (LPA) signalling reduced HCV replication, 
demonstrating a positive role for this phospholipase in the viral life 
cycle. LPA activates phosphoinositide-3-kinase that stabilizes HIF-1α and 
inhibiting the HIF-signalling pathway abrogates the pro-viral activity of 
LPA. Conclusions: Our data support a model where HCV infection increases 
ATX expression that supports viral replication and HCC progression.  
 
 
Response to Reviewers: A file containing the responses has been uploaded 
as a PDF file. 
 
University of Birmingham, Edgbaston, Birmingham, B15 2TT, United Kingdom 
T: +44 (0) 121 414 8173 F: +44 (0) 121 414 3599 E: j.a.mckeating@bham.ac.uk W: www.infection,bham.ac.uk/VRG 
 	
	
	
	
	
	
	
	
	
Journal	of	Hepatology	Editors		
8th	Dec	2016	
Resubmission	 of	 manuscript	 JHEPAT-D-16-01414R	 ‘Autotaxin-lysophosphatidic	 acid	 receptor	
signalling	regulates	hepatitis	C	virus	replication’	
Dear	Editors		
	
We	are	pleased	to	submit	our	revised	manuscript	on	the	role	of	autotaxin	in	the	hepatitis	C	virus	
lifecycle.	We’d	like	to	take	this	opportunity	to	thank	the	reviewers	for	their	constructive	comments	
and	provide	a	point-by-point	response	in	the	attached	document.	We	believe	the	manuscript	has	
been	improved	by	these	revisions	and	we	look	forward	to	a	favourable	response.		
	
With	my	best	wishes,		
	
	
	
	
	
	
	
Jane	A	McKeating.	
	
Professor	of	Molecular	Virology.	
THE UNIVERSITY 
OF BIRMINGHAM 
 
Centre for Human Virology  
MRC Centre for Immune Regulation 
NIHR Centre for Liver Disease 
The Medical School 
University of Birmingham 
Edgbaston 
Birmingham B15 2TT 
United Kingdom 
 
Professor of Molecular Virology 
Tel: 0121 414 8173 
Email: j.a.mckeating@bham.ac.uk 
B
i
r
m
i
n
g
h
a
m
 
B
1
5
 
2
T
T 
U
n
i
t
e
d
 
K
i
n
g
d
o
m 
T
e
l
e
p
h
o
n
e
 
0
1
2
1
 
4
1
4
 
6
9
1
3 
F
a
x
 
0
1
2
1
 
4
1
4
 
6
9
1
Cover Letter
 Responses to reviewers comments: 
 
Reviewer #1: In this manuscript Farquhar and colleagues investigate the role of hypoxia in the 
regulation of autotaxin expression - which the authors describe as a novel pathway to modulate 
hepatitis C virus replication and HCC development. This is an interesting study, that in most of the 
parts is well controlled. Still, I believe that the paper needs several additional experiments and 
controls. Several molecular aspects of action are not clear and should be worked on. 
 
Title: It is not clear where the authors show modulation of hepatocellular carcinoma. Thus, in case 
not clearly shown "hepatocellular carcinogenesis" should be omitted in the title. This can be and is 
discussed in the text but in case no data are shown it should not be put in the title. Response: We 
have edited the title to remove HCC pathogenesis. However, we have also included some new data 
in Fig.3c showing an association between high ATX RNA expression in HBV-associated HCC 
progression. 
 
Figure 1a - It is not clear what is demonstrated in the two ATX blots in panel a. Why are there two 
bands in the cell vs. extracellular? Other loading control than beta-actin? The induction of ATX is 
impressive - loading control for the second ATX blot? kDa are missing! Response: ATX is a 
glycoprotein and the multiple bands in the cellular fraction represent glycosylated and non-
glycosylated forms, whereas secreted ATX runs as a single band representing the glycosylated 
protein.  
 
Fig.1b - The trend in PHH is visible - so convincing for me - maybe one could increase the n of PHH 
samples so that this trend is seen in 5 PHH samples altogether? Response: The chimeric SCID-upA 
mice are difficult to breed and our inclusion of data from several animals transplanted with PHH 
from three donors exceeds sample numbers included in many published reports using this model. 
Given these difficulties and the statistical significance of our results with three donors we believe 
the conclusions from these studies are valid.  
 
Fig.1c - Scale bar is missing - special staining? Controls to show specificity? Cell of expression - is 
it the virus-infected cells - the neighbouring cells or both? Response: The revised figure includes 
irrelevant isotype stained liver sections and we have noted the x400 magnification in the figure 
legend. Since ATX is a secreted protein that can be taken up by diverse cell types we have revised 
the text in the manuscript to reflect this and to interpret the stains with care. It is notoriously 
difficult to visualize HCV antigen expressing hepatocytes in liver tissue from the chimeric mouse 
model or in infected patients and so it is beyond the scope of the current study to co-stain liver 
sections for ATX and viral encoded antigens or RNA.  
  
Fig.1d -  More Huh-7 cells to be shown (at least 3?). Response: We have replotted graph to show 
additional biological replicates.   
 
Fig.1e and f -  Link to different oxygenation? HIF expression? Histology to show a representative 
image? Response: The impact of local oxygen tension on the HCC microenvironment is an 
important research question that may be best answered using oxygen sensitive imaging 
techniques that are beyond the scope of this project. Given the difficulties stated above in 
interpreting anti-ATX stained biopsies we have deferred from staining the HCC tissues.  
 
Fig.2: How does ATX expression develop under pHIF1alpha by WB in Figure 2a? Response: 
Transient over-expression of HIF1a under normoxic conditions alters the balance between genesis: 
degradation, and promotes HIF-transcriptional responses as seen with VEGF mRNA levels.  
 
Fig. 3a - How does HA130 treatment affect ATX expression? Response: HA130 is an antagonist of 
ATX enzymic activity and has no observed effect on ATX protein levels in our study or in the 
published literature.  
 
Fig.3d - These experiments are very nice. However, the quality of the WB should be increased. It 
is not quite clear - in general all WBs lack kDa indication. Response: We have included the kDa 
markers in the revised figures. 
 
Fig.4a -  It is not clear how the different doses of LPA change cell integrity (e.g. proliferation, cell 
survival, expression of markers that support virus replication; this should be tested). Response: 
LPA had no discernable effect on hepatocyte morphology and promoted cellular proliferation, 
justifying our experiment (Fig.4f) to evaluate the effect of HA130 on HCV replication in growth 
arrested cells. These data suggest that the anti-viral activity of HA130 is independent of the 
proliferative status of the target cell.   
*Detailed Response to Reviewers
 
Fig.4b - These data are convincing and very interesting. Is it possible to dissect LPA1 and 3?  
Response: We have included LPA receptor RNA expression data in the revised Ms but further 
dissection of receptors would require shRNA or CRISPR and is beyond the scope of the current 
study.   
 
Fig 5c: What additional effect does the high dose of HA130 (100 nm) have - are the effects directly 
attributable to suppression of ATX enzymatic activity? (Cell integrity? Apoptosis, survival, changes 
in the replication machinery?) Response: no effects, ATX inhibitors have been safely used in 
clinical trials. 
 
If the mechanism of HA130 is directly on ATX function - what are the downstream players that are 
changed.  Response: Fig.7 of the revised manuscript shows a role for LPA to activate PI3K and 
stabilize HIF-1a and we believe this signaling pathway promotes HCV RNA replication. We have 
provided a cartoon of the ATX-LPA signaling pathway in the HCV replicative life cycle (Fig.7f). 
 
Could the authors investigate to some degree the underlying mechanisms of ATX inhibition and 
reduction in viral replication? To get some more insight on this would be important! It is not clear 
how this works. Response: Please see our response above and provision of ATX-LPA signaling 
pathway in Fig.7f.  
 
Fig.6b: The Akt phsphorylation is interesting indeed - is this something that is reproducible in 
other cells or PHH? Or is this specific to Huh-7 cells?  Response: LPA activates PI3K and thus AKT 
in a range of cell types – please see our earlier report - Jethwa SA, Leah EJ, Zhang Q, Bright NA, 
Oxley D, Bootman MD, Rudge SA, Wakelam MJO. (2016) “Exosomes bind autotaxin and act as a 
physiological delivery mechanism to stimulate LPA receptor signalling in cells.” J Cell Sci. 129, 
3948-3957. 
 
In the context of LPA-activated PI3-kinase signalling in stabilizing HIF1a and HCV replication it 
would be important to show this in other cell systems. Response: Several citations are provided in 
the manuscript that reference LPA stabilizing HIF1a in other cell systems. 
 
 On the whole this is an interesting paper - the title I believe is partially misleading as no real data 
on hepatocellular carcinogenesis are presented. So this should be omitted - I agree that the LPA 
signalling pathway might be an interesting target but this has not been shown in regards to HCC 
development. Also I believe the paper ends fast, but mechanistically several things are not clear. 
Response: We have revised the title of the paper to exclude hepatocellular carcinogenesis. In 
addition we include new data in Fig.3c to ascertain the relationship between ATX RNA levels and 
HCC pathogenesis and believe this strengthens our study.  
 
----------------------------------------------------- 
Reviewer #2: In their current manuscript, the authors investigate the regulation of autotaxin 
(ATX) and LPA signaling in the contexts of HCV infection and hypoxia. They describe, for the first 
time to my knowledge, that HCV infection upregulates ATX expression on both, transcriptional and 
protein levels, which in turn leads to the generation of the messenger molecule LPA. The authors 
furthermore show that ATX is also upregulated by low oxygen conditions (hypoxia), most probably 
through upregulation of the transcription factor HIF1a. Vice versa, they also describe upregulation 
of HIF1a by ATX / autocrine LPA signaling through the PI3K/AKT pathway. Lastly, they confirm 
their previous finding that inhibition/knockdown of HIF1a substantially impacts on HCV replication. 
 
LPA signaling has been implicated with numerous malignancies, and ATX / LPA signaling are 
getting into the focus of researchers as anti-cancer targets (e.g. PMID: 25704398). Therefore, the 
authors' current finding of HCV-induced upregulation of ATX/LPA signaling is very interesting and 
proposes this process as a potential mechanism of carcinogenesis or at least as a tumor promoting 
factor in hepatitis C. 
 
The manuscript is written and presented very clearly, concisely and comprehensibly. Data is 
presented in a clear and meaningful way, with almost all controls included, and statistical 
significance indicated where possible and necessary. For the largest part, the observed effects are 
unambiguous and the authors' conclusions are justified. 
 
While reading the manuscript was pleasant and following the experiments was straightforward, the 
paper left one regrettably big question unanswered: the chicken and egg dilemma. The authors 
and a more or less ample set of published studies show many co-regulations and 
interdependences: HCV induces ATX; ATX produces LPA, which induces HIF1a; HIF1a again 
induces ATX; hypoxia induces HIF1a AND ATX; HIF1a and LPA promote HCV replication and 
suppression of each also suppresses HCV. 
 
Each effect alone is convincing, but together they leave the reader dizzy with no clear 
understanding of what is actually going on. In fact, it seems as if the authors themselves are not 
exactly sure, where they should be heading. The title of their story is "hypoxia regulates ATX 
expression", but Figure 1 first shows that HCV infection regulates ATX expression (which is 
interesting and important!) and secondly that hypoxia can do the same independent of the virus. 
For the whole rest of the story, hypoxia is unimportant and everything is centered around HCV 
(which does it all even under normoxia).   
 
Response: We have included two new pieces of data and revised text to address this reviewers 
comments and provided a cartoon to describe our model (Fig.7f).  
(1) Time course of VEGF and ATX expression following HCV infection – showing HIF target 
gene precedes ATX upregulation.  
(2) The HIF pathway inhibitor NSC reduces the pro-viral activity of LPA, supporting our model 
that LPA primed HCV infection is HIF-dependent. 
 
Does HCV lead (as one would expect from the strong ATX upregulation) to an increase in LPA 
production, and if so, of which subtype? Might this suffice to induce HIF1a? Response: The 
requirement on safety grounds to ‘heat inactivate infectious HCV’ prior to mass spec analysis has 
distorted our LPA recovery and provided uncontrollable variable data. Despite our best efforts we 
have been unable to perform this experiment and we state this in the revised manuscript. 
 
This leads to this question: is HIF1a still upregulated / stabilized by HCV if treated with LPAR-
antagonist? If not, this would be a strong case for indirect HIF1a upregulation by HCV in contrast 
to direct stabilization. Response: Please see above and the new data presented in Fig.7b. 
 
These are all just suggestions, which might or might not make sense. However, I do have the 
strong feeling that- despite the high quality of the science as it is currently already-  it would 
require addressing such more causal / mechanistic aspects to make the manuscript ready for 
publication; this does not require a massive amount of additional experimentation. Response: We 
thank this reviewer for their excellent suggestions to improve the clarity of our manuscript and we 
believe our additional data along with text edits have addressed their concerns.  
 
Beyond these more general issues, there are a few more technical points I would like to raise and 
propose the authors to modify in a potential revision:  
 
Albeit difficult, I would very much suggest using a second, constitutively secreted protein as a 
control for the extracellular ATX Western blots. Would albumin work? Or some cytokine? If not, at 
least one control experiment showing HCV and hypoxia mediated ATX upregulation has to be 
performed with cells artificially secreting a control protein, e.g. Gaussia luciferase. Otherwise, 
controlling for cell numbers etc. is very difficult. Response: We controlled for cell numbers in all 
experiments and have stated this in the revised text.  
 
Are really no other LPARs capable of mediating the observed effect? It seems like a luck shot, that 
the one and only tested inhibitor does the whole job. LPAR5 would of course be a hot candidate as 
it is expressed in liver (in contrast to LPAR1 and 2). Lacking an inhibitor, this would require RNAi, 
though. Response: We provide transcript data in Fig.5c to show that Huh-7 cells and PHHs express 
all LPARs, with the exception of LPAR4. Further studies to explore the LPAR dependency of LPA 
signaling in the HCV life cycle would require silencing of all six receptors and given the limited 
availability of validated antibodies this is beyond the scope of the current study.  
 
Fig.4A: This experiment should better be done in DMSO "differentiated" cells. A 100-fold difference 
in LPA concentration yields only a less than 2.5-fold increase in HCV replication - may this be the 
pro-proliferative effect of LPA? Response: Data not provided in current Ms shows that DMSO 
‘differentiated’ cells show a 100-fold reduced permissivity to support replication and we think this 
may be due to their blunted HIF response, this is the subject of an independent manuscript.   
 
1. Fig.1 C should get a label ("ATX").  
 
2. Fig. 1 E: I do not understand the Y-scale. What is a relative expression of -2? 
 
3. All y-axes labels "Relative ATX expression" should make clear that mRNA is measured 
 
4. Fig. 6D: labels misleading; make clearer that all four samples are LPA treated and are 
normalized to the LPA untreated, inhibitor untreated sample, which is not shown (or show it!). 
Response: we have revised figures and text to respond to all of these points. 
 
----------------------------------------------------- 
 
Reviewer #3: The authors demonstrate that autotaxin (ATX) has a positive effect on the HCV 
replication and provide evidence indicating that ATX expression is up-regulated under low oxygen 
conditions in a HIF-dependent manner. This was based on the use of in vitro hepatocyte cultures, 
chimeric humanized liver mice, HCC tissue and ex vivo liver culture systems. Furthermore, they 
claim that HCV infection increases hepatocellular ATX expression via stabilizing hypoxia inducible 
factor (HIF). Based on these data they propose a model suggesting that "HCV infection may 
increase hepatocellular ATX expression via HIF1 activation and that increases viral replication and 
establishes a paracrine LPA-signalling environment that drives fibrosis, cirrhosis and HCC 
pathogenesis" 
 
The following points should be considered: 
 
The authors provide evidence indicating that low oxygen conditions or HCV infection independently 
positively regulate ATX expression.  Provided that liver microenvironment is hypoxic, I recommend 
to test ATX expression in HCV-infected cells under low oxygen conditions and, should this be the 
case, to test the role of HIF. Response: Since low oxygen potentiates HCV infection (manuscript in 
preparation) and increases both the frequency of viral antigen expressing cells and their viral RNA 
burden – it would be difficult to discriminate the additive effects of these two cellular stresses on 
ATX expression. Given the anti-viral effects of siRNA HIF-1a and the complexities of discriminating 
between low oxygen and HCV infection induced changes in ATX expression we would defer from 
including this experiment in our manuscript.  
 
Vassilaki et al. JVI 2013 reported that low oxygen conditions stimulate HCV replication in cultured 
cells and provided data that associate this phenomenon with HIF-independent changes of the 
cellular bioenergetics under low oxygen. Authors may wish to discuss this publication accordingly. 
 Response: We have cited and discussed this work in our revised manuscript. 
 
Page 4, lines 5-9: "Human hepatocytes in the transplanted mice expressed comparable levels of 
ATX mRNA to Huh-7 cells, however, following isolation and short-term propagation the PHHs 
showed significantly lower levels of ATX mRNA (Fig. 1d) that may reflect their de-differentiation in 
vitro". Again, I recommend to perform these experiment under low oxygen conditions. 
Furthermore, authors may show experimental evidence for the proposed de-differentiation. 
Response: We have revised our manuscript to state that PHHs show reduced levels of hepatocyte 
specific differentiation markers compared to human liver tissue, suggesting a de-differentiation of 
the cells in vitro. We would be very interested to investigate the effect of low oxygen on human 
hepatocellular ATX expression and this would be most elegantly assessed using the chimeric 
human-mouse liver tissue. Unfortunately since the mice are housed in our collaborator Prof 
Baumerts laboratory in Strasbourg this experiment has not been possible at the present time.  
 
Fig 2b: Data from statistical analysis are presented only for the ATX mRNA. Present/discuss 
statistical analysis for the mRNA levels of the control VEGF or GLUT1 genes. Response: We 
provides stats for these data in the revised manuscript. 
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Abstract:  
Background and aims: Chronic hepatitis C is a global health problem with an estimated 
170 million HCV infected individuals at risk of progressive liver disease and hepatocellular 
carcinoma (HCC). Autotaxin (ATX) is a phospholipase with diverse roles in physiological and 
pathological processes including inflammation and oncogenesis. Clinical studies have 
reported increased ATX expression in chronic hepatitis C, however, the pathways regulating 
ATX and its role in the viral life cycle are not well understood. Methods: In vitro hepatocyte 
and ex vivo liver culture systems along with chimeric humanized liver mice and HCC tissue 
enabled us to assess the interplay between ATX and the HCV life cycle. Results: HCV 
infection increased hepatocellular ATX RNA and protein expression. HCV infection stabilizes 
hypoxia inducible factors (HIFs) and we investigated a role for these transcription factors to 
regulate ATX. In vitro studies show that low oxygen increases hepatocellular ATX expression 
and transcriptome analysis showed a positive correlation between ATX mRNA levels and 
hypoxia gene score in HCC tumor tissue associated with HCV and other aetiologies. 
Importantly, inhibiting ATX-lysophosphatidic acid (LPA) signalling reduced HCV replication, 
demonstrating a positive role for this phospholipase in the viral life cycle. LPA activates 
phosphoinositide-3-kinase that stabilizes HIF-1α and inhibiting the HIF-signalling pathway 
abrogates the pro-viral activity of LPA. Conclusions: Our data support a model where HCV 
infection increases ATX expression that supports viral replication and HCC progression.  
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Introduction: Chronic viral hepatitis is a global health problem with at least 170 million 
hepatitis C virus (HCV) infected individuals at risk of developing liver disease that can 
progress to hepatocellular carcinoma (HCC). The recent availability of direct acting anti-viral 
agents can eliminate HCV in up to 90% of patients[1]. However, the high cost of these drugs 
along with reports of viral genotype resistance, may limit their wide-spread use. Importantly, 
patients with liver cirrhosis cured of HCV may remain at risk of developing HCC, highlighting 
the need to understand host pathways playing a role in HCC development[2, 3]. 
 
Autotaxin (ATX) is a member of the ectonucleotide pyrophosphatase/phosphodiesterase 
family of proteins that was identified as a motility-stimulating factor secreted from 
melanoma cells[4]. ATX hydrolyzes lysophosphatidylcholine (LPC) to lysophosphatidic acid 
(LPA), a growth factor that activates and signals via a family of six G-protein coupled LPA 
receptors (LPA1-6). The ATX-LPA signalling axis has been reported to play a tumorigenic role 
in a wide number of cancers and is a candidate for therapeutic intervention[5]. Several 
studies have reported increased ATX and LPA levels in the plasma of HCV infected subjects 
that associates with liver fibrosis staging[6-9]. A recent prospective study showed that 
serum ATX predicts the severity of liver cirrhosis and prognosis of cirrhotic patients[10]. 
Mazzocca and colleagues reported that HCC secreted LPA increases the trans-differentiation 
of peritumoral fibroblasts to carcinoma associated fibroblasts that are considered to play a 
role in tumour proliferation and metastasis[11].  
 
ATX is expressed in many tissues and the mechanisms accounting for increased serum 
phospholipase activity in chronic hepatitis C and the impact on viral replication are not 
understood. We show that HCV infection of hepatocyte-derived cells or mice with humanized 
chimeric livers increases ATX mRNA and protein expression. Infection stabilizes hypoxia 
inducible factor-1 (HIF-1)[12, 13] and we show that low oxygen increases ATX transcripts 
in human liver slices, suggesting a pathway for HCV to regulate ATX. We demonstrate a 
positive association between ATX and hypoxia related gene expression in viral and non-viral 
HCC, providing an explanation for elevated ATX expression in tumors that are frequently 
hypoxic. Finally, we demonstrate that ATX-LPA signalling regulates HCV RNA replication via a 
phosphoinositide 3 kinase (PI3K) dependent pathway, demonstrating a role for 
lysophospholipids in viral infection. Our data support a model where HCV infection increases 
hepatocellular ATX expression that promotes viral replication and establishes a paracrine 
LPA-signalling environment leading to fibrosis and HCC pathogenesis.  
 
Results 
 
HCV infection and low oxygen induce autotaxin expression. To ascertain whether HCV 
infection directly regulates ATX expression we selected Huh-7 hepatocyte-derived cells as a 
permissive target cell that supports HCV replication. In vitro tissue culture protocols routinely 
use media containing bovine serum that contains high levels of ATX that can catalyse LPC-
LPA conversion. We therefore performed all experiments under serum-free conditions to limit 
the confounding effects of de novo generated bovine LPA. Huh-7 cells express ATX and the 
majority of protein is detected in the extracellular media (Fig.1a). HCV (strain J6/JFH) 
infection induced a significant increase in ATX mRNA and protein expression (Fig.1a). 
Experiments to assess the effect of HCV infection on primary human hepatocyte (PHH) ATX 
expression were inconclusive due to their low permissivity under serum-free conditions 
required to interrogate human ATX function.  
 
The uPA-SCID human liver chimeric mouse supports HCV infection[14] and enables us to 
study the effect of viral infection on hepatocellular ATX expression in vivo. Since ATX is likely 
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to be expressed by multiple cell types in the human liver this murine model provides a 
unique opportunity to ascertain whether hepatocytes express ATX. All mice engrafted with 
human hepatocytes express human ATX and infection increased ATX mRNA levels, 
independent of the hepatocyte donor (Fig.1b). In non-transplanted mice we failed to detect 
ATX expression illustrating both the specificity of the primers for human ATX and 
demonstrating that HCV-dependent modulation of ATX is of human hepatocyte origin. It is 
interesting to note that hepatocytes in the transplanted mice express comparable levels of 
ATX mRNA to Huh-7 cells, however, following isolation and short-term propagation PHHs had 
lower ATX mRNA levels (Fig.1c). We noted a 10-20 fold reduction in mRNA levels of 
hepatocyte specific markers (Albumin, CYP3A4 and HNF4α) in cultured PHHs during the first 
48h of culture, most likely reflecting their de-differentiation. Immunohistochemical staining 
of the chimeric murine-human livers showed hepatocytes expressing ATX in the HCV infected 
animals (Fig.1d), however, given the secreted nature of this protein we should interpret 
these data with care with respect to the cellular source of the stained ATX. Next, we sought 
to analyse ATX RNA levels in HCC from patients diagnosed with HCV, hepatitis B virus (HBV) 
and alcoholic liver disease (ALD) [15, 16]. Transcriptomic analysis showed a significant 
increase of ATX in HCV-associated HCC but also in subjects with HBV and ALD compared to 
normal liver (NL) (Fig.1e). A pairwise analysis of tumour and non-tumour tissue from a 
cohort of 233 Chinese patients with HBV-associated HCC showed that ATX is significantly 
upregulated in tumour compared to non-tumour tissue (Fig.1f). 
 
We observed increased ATX mRNA levels in HCV-infected mice, HCC tumours and Huh-7 cells 
suggesting that infection perturbs ATX at the transcriptional level. Since HCV can stabilize 
hypoxia inducible factor 1α (HIF-1-α) [12, 13] we investigated a potential role for this 
transcription factor to regulate ATX. Under normoxia HIF-α subunits are rapidly targeted for 
proteosomal degradation by prolyl hydroxylases, however, under low oxygen conditions 
these hydroxylases are inactivated resulting in stable HIF expression. Huh-7 cells were 
cultured under normoxic (20%O2) or hypoxic (1%O2) conditions for 24h and ATX mRNA 
levels along with HIF-target genes VEGF and GLUT1 were quantified. We confirmed HIF-1α 
expression by Western blotting and observed a significant increase in ATX, VEGF and GLUT1 
mRNA and secreted ATX from Huh-7 cells cultured under low oxygen (Fig.2a).  
 
To analyse a role for HIF-1α in regulating ATX expression, Huh-7 cells were transfected with 
a plasmid encoding HIF-1α to express the transcription factor under normoxic conditions. We 
demonstrated a modest level of HIF-1α expression and increased ATX and VEGF mRNA levels 
(Fig.2a), suggesting a role for HIF in regulating ATX transcription. Further studies 
investigated the effect of low oxygen on ATX expression in human liver slices. Liver slices 
from 5 independent donors cultured under normoxic or hypoxic conditions for 24h showed a 
significant increase in ATX, VEGF and GLUT1 mRNA levels (Fig.2b), demonstrating a role for 
low oxygen in regulating ATX expression in human liver tissue. To ascertain whether low 
oxygen regulates ATX promoter activity we cloned the published promoter region[7] into a 
reporter plasmid and quantified luciferase activity in Huh-7 cells cultured under normoxic or 
hypoxic conditions for 24h. The ATX promoter plasmid showed an approximate 2-log 
increase in luciferase activity compared to vector alone, however, this was not increased by 
culturing the cells under hypoxic conditions (Fig.2c). As a control Huh-7 expressing a 
hypoxia responsive element (HRE) reporter, showed a 200-fold increase in luciferase activity 
(Fig.2c). The negligible effect of low oxygen on ATX promoter activity is consistent with the 
absence of HREs in this region and the lack of HIF-1α binding to this region in HepG2 
hepatoma cells by ChIP-SEQ (David Mole, personal communication). Collectively, these data 
support an indirect role for HIF-1 to regulate ATX transcription.  
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 5 
To understand whether HCV upregulates ATX expression via a HIF-dependent pathway we 
quantified ATX and VEGF mRNA levels over time and only observed a significant increase in 
ATX mRNA levels 48h post infection (Fig.2d). In contrast, we observed increased VEGF 
mRNA levels after 24h and they remained elevated for the duration of the experiment 
(Fig.2d). Assuming similar half-lives for these two RNA species these data support a model 
where HCV stabilized HIF-transcriptional activity precedes ATX upregulation. To validate 
these conclusions we siRNA silenced HIF-1α in Huh-7 cells to assess its role in viral 
regulation of ATX and Western blotting confirmed effective silencing under low oxygen 
conditions (Fig.2e). However we failed to infect these cells, suggesting a role for HIF-1 in 
the HCV life cycle as previously reported[13] but preventing confirmation of this pathway in 
viral regulation of ATX. 
 
To extend our observations that hypoxia regulates ATX we studied the relationship between 
ATX and hypoxia gene transcript levels in HCC. van Malenstein et al identified a seven gene 
‘hypoxia signature’ that was elevated in HCC[17]. We investigated the expression of these 
genes in our HCC cohorts. We noted a significant deregulation of five out of seven hypoxia-
regulated genes and a significant increase in the hypoxia score in HCC associated with all 
aetiologies compared to NL (Supplementary Fig.1). Since the time of processing liver 
samples can vary and may result in oxygen deprivation and HIF expression, we selected to 
study the HBV cohort where tumour and adjacent non-tumour tissue was available, enabling 
us to limit sampling artefacts and to conduct pairwise comparisons. We observed an 
increased hypoxia gene score in HCC compared to matched non-tumour tissues (Fig.3a). 
Furthermore, we noted a positive correlation between ATX mRNA and the hypoxia gene 
signature (Fig.3b). Due to the reported association of hypoxia and patient survival, we 
asked whether ATX gene expression associates with patient outcome[17]. Patients were 
classified in two groups based on the median difference of ATX expression between tumour 
and non-tumour tissues. Kaplan-Meier survival curves revealed that patients with high ATX 
expression had shorter survival times compared to low expression, although this difference 
was not statistically significant (log-rank p-value) (Fig.3c). Thus, we could confirm that the 
Hypoxia score is increased in HCC tumour tissue compared to adjacent non-tumour tissue 
and ATX mRNA expression positively correlates with the Hypoxia gene signature supporting a 
role for hypoxia to regulate ATX-LPA signalling in HCC development. 
 
Autotaxin-LPA signalling axis in HCV infection. To investigate a role for ATX in the HCV 
life cycle we treated Huh-7 cells with HA130, a selective inhibitor of ATX enzymatic 
activity[18]. HA130 had no effect on Huh-7 viability but significantly reduced LPA levels 
(Fig.4a). LPA is not a single entity and mass spectrometric analysis shows that Huh-7 
generate several species of differing acyl chain lengths and degrees of saturation, with 16:0 
and 18:1 being the most abundant. Statistical analysis of the results from five independent 
experiments showed a significant reduction in 18:1, 18:2, 20:4 and 22:6 LPA levels from 
HA130 treated cells compared to the untreated control. In contrast, HA130 had no significant 
effect on expression of LPA species 14:0, 16:0 or 18:0 (Fig.4a). We observed a dose-
dependent HA130 inhibition of HCV J6/JFH and SA13/JFH infection (Fig.4b). To confirm 
these observations, Huh-7 cells were transduced with an shRNA targeting ATX or an 
irrelevant control. RT-PCR and Western blotting confirmed a reduction in ATX expression and 
HCV infection (Fig.4c). Since off-target effects are a common limitation of gene silencing, we 
performed a rescue experiment where ATX-silenced cells were transfected to express wild 
type (ATXwt) or a catalytically inactive mutant (ATXT210A). Exogenous expression of ATXwt in 
silenced cells restored infection to levels seen in irrelevant shRNA transduced cells, whereas 
the ATXT210A mutant had no effect (Fig.4d). Of note, expressing ATXwt in shControl or non-
transduced Huh-7 cells increased the frequency of HCV infected cells, suggesting that ATX 
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 6 
levels may be limiting. We confirmed that silencing ATX ablated the anti-viral effect of HA130 
and exogenous LPA restored HCV infection (Fig.4e). To determine whether HCV increased 
ATX expression drives higher LPA generation we attempted to quantify LPA species in mock 
and infected samples by mass spectrometry. Unfortunately, the protocol necessary to 
inactivate the virus prior to analysis, heating the samples at 65oC for 10 minutes, caused a 
2-3 fold increase in all molecular LPA species most likely explained by heat-induced LPC 
breakdown. Alternative inactivation protocols involving addition of chloroform/methanol 
mixtures to the samples were tested but were incompatible with the extraction procedure 
used for LC-MS analysis.  
 
LPA can regulate cellular proliferation and HA130 treated Huh-7 cells show an increased 
doubling time from 17h to 23h. To assess whether the anti-viral effect of HA130 is 
dependent on Huh-7 proliferative status we used DMSO-arrested and differentiated Huh-7 
cells[19]. We confirmed that the Huh-7 were cell cycle-arrested and showed increased levels 
of differentiation markers albumin, CYP3A4 and HNF4- (Fig.4f). The differentiation protocol 
had no effect on ATX mRNA levels and treating with HA130 reduced HCV infection to a level 
comparable seen with non-differentiated cells (Fig.4f), demonstrating that viral inhibition is 
not linked to the proliferative status of the target cell. 
 
Since our experiments demonstrate a requirement for the lysophospholipase activity of ATX 
in HCV infection, we investigated the effect of exogenous LPA (18:1) on Huh-7 permissivity 
for HCV infection. LPA enhanced HCV infection in a dose-dependent manner (Fig.5a). To 
investigate the receptor dependency of LPA-augmented HCV infection, cells were incubated 
with LPA in the presence or absence of the LPA1/3 antagonist Ki16425[20]. Ki16425 
abrogated the pro-viral activity of LPA for HCV infectivity (Fig.5b), demonstrating a role for 
LPA1 or LPA3 in HCV infection. LPA binds and signals through a family of six LPA receptors 
and Huh-7 cells express mRNA for each of the receptors with the exception of LPA4 at 
comparable levels to PHHs (Fig.5c). 
 
A role for autotaxin in the HCV lifecycle. To assess whether ATX has a specific role in 
HCV entry into hepatocytes, we used lentiviral pseudoparticles expressing HCV E1E2 
glycoproteins to measure glycoprotein-receptor entry. We selected HCV strain H77 and 1A38 
glycoproteins as they routinely provide the most infectious pseudoparticle stocks[21]. HA130 
had no effect on HCVpp infection (Fig.6a), similar observations were made with viruses 
expressing a range of HCV glycoproteins (data not shown). To investigate a role for ATX-LPA 
signalling in HCV RNA replication we treated Huh-7 cells stably expressing a subgenomic HCV 
replicon encoding a luciferase reporter (Luc2a-JFH) with HA130 or shATX and noted a 
significant reduction in luciferase activity (Fig.6b). To assess whether HA130 treatment of 
naïve Huh-7 cells could limit the initiation of HCV RNA replication, Huh-7 cells were 
transfected with a full-length HCV RNA encoding a secreted gaussia luciferase (JC1GLuc) and 
we noted a dose-dependent HA130 inhibition of replication (Fig.6c). These studies show that 
inhibiting ATX reduced HCV RNA replication in stably transfected cells and in naïve cells 
challenged with virus, demonstrating a role for the ATX-LPA signalling in the initiation and 
maintenance of viral replication.  
 
LPA was reported to stabilize HIF-1α expression in ovarian and colon cancer cells[22] and we 
investigated a role for HIF-1α in LPA-dependent HCV infection. We show that LPA stabilized 
HIF-1α under normoxic conditions and increased HRE-transcriptional reporter activity that 
was inhibited by Ki16425 (Fig.7a), demonstrating LPA1/3 dependent signalling. We previously 
reported that the HIF-pathway inhibitor NSC-134754[23] reduced hepatocellular HIF-1α 
expression and HCV replication[13]. Titration of NSC-134754 identified a sub-saturating 
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 7 
concentration (25nM) that reduced HIF-transcriptional reporter activity with minimal effect 
on HCV replication and demonstrated a role for the HIF-signalling pathway in the pro-viral 
activity of LPA (Fig.7b). Previous studies reported a role for PI3K activation in LPA-
dependent stabilization of HIF-1α[24] and we found that LPA induced AKT phosphorylation in 
Huh-7 cells (Fig.7c). Pre-incubating the cells with the pan PI-3-kinase inhibitor wortmannin 
(WM) or BYL-719, that selectively targets p110 class IA PI-3-kinase, abrogated HIF-1α 
expression (Fig.7d). In contrast, LPA-stimulated HIF-1α expression was insensitive to the 
presence of p110 class IA PI3K inhibitor TGX-221 (Fig.7d). To establish a role for the PI-3-
kinase pathway in LPA-stimulated HCV infection we assessed the ability of these inhibitors to 
modulate infection. WM and BYL-719 treatments ablated the LPA enhancement of HCV 
infection whereas TGX-221 had no effect (Fig.7e). In summary, these data demonstrate a 
role for LPA-activated PI-3-kinase signalling in stabilizing HIF-1α that regulates HCV 
replication (Fig.7f). 
 
Discussion: Our studies uncover a role for the ATX-LPA signalling axis to positively regulate 
HCV RNA replication by activating PI3K and stabilizing HIF-1α (Fig.7f). Inhibiting ATX 
activity or LPA signalling reduced HCV replication, providing evidence for an autocrine LPA-
feedback loop to promote viral replication. PI3K signalling has been reported to positively 
regulate HCV replication[25] and suppressing this pathway inhibits HCV replication [26, 27]. 
We previously reported that low oxygen stabilized HIF promotes HCV infection[13] and our 
current study showing that silencing HIF-1α limits HCV replication, suggests a role for this 
pathway in LPA-induced infection. Vassilaki et al reported that low oxygen stimulated HCV 
replication[28], however, the authors concluded that this phenotype was independent of HIF-
1α or HIF-2α that may reflect the use of different Huh-7 cell clones or partial HIF-silencing. 
Our observation that LPA stabilized hepatocellular HIF-1α and is consistent with reports 
showing a role for LPA to ‘rescue’ mesenchymal stromal cells[29] or human CD34+ cells[30] 
in ischemic disease and are most likely explained by its ability to activate HIF signalling.   
 
We demonstrate a role for low oxygen to regulate ATX mRNA in hepatocyte-derived Huh-7 
cells and human liver slices, consistent with reports of increased ATX expression in a variety 
of tumours that are frequently hypoxic. Importantly, we show a positive association between 
elevated ATX mRNA levels in HCC and the hypoxia gene score. Transient over-expression of 
HIF-1 in Huh-7 cells increases ATX mRNA, suggesting an activating role for this 
transcription factor. However, low oxygen had a minimal effect on ATX promoter activity, in 
agreement with the lack of HRE sites in this region and suggesting that enhancer regions 
beyond the published 1.2kb promoter may bind HIFs or that low oxygen regulated factors 
increase ATX mRNA half-life and/or protein stability. Wu and colleagues reported that TNF 
induced a modest 3-fold increase in ATX mRNA levels in HepG2 cells via nuclear factor kappa 
beta activation[7]. However, we failed to see any evidence for TNF modulation of ATX 
promoter activity in Huh-7 cells or human liver slices, suggesting that this may be cell type 
dependent. 
 
ATX is expressed in many tissues, however the source of elevated ATX in the sera of chronic 
hepatitis C patients is unknown. Our studies with chimeric liver uPA-SCID mice show that 
hepatocytes express ATX and HCV infection induces its expression in the absence of any 
inflammatory response. We confirmed increased ATX transcript levels in HCC tumour tissues 
from subjects with HCV, HBV and ALD aetiologies, demonstrating that increased ATX 
expression is not unique to HCV infection. Reports that HBV can stabilize HIF[31] and ALD is 
associated with hepatic HIF expression[32] lend support to our model that HIFs regulate 
hepatic ATX expression. In the healthy liver ATX is most likely removed from the circulation 
by sinusoidal endothelial cells[33], however, during fibrosis phenotypic changes in the 
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 8 
sinusoidal endothelium[34] are likely to impair ATX clearance that may account for the 
increased expression reported in the fibrotic liver. However, these morphological changes are 
unlikely to account for the increase in ATX mRNA observed in this study. It is interesting to 
note that Epstein Barr virus (EBV) infection of Hodgkin lymphoma cells induces ATX 
expression that augments their proliferation and survival[35]. EBV is an oncogenic virus 
associated with B-lymphoid and non-lymphoid malignancies that is known to stabilize HIF-
1[36], suggesting a common pathway for viruses to activate the ATX-LPA signalling axis. 
 
LPA is not a single entity and exists in several forms with differing acyl chain lengths and 
degrees of saturation that interact with specific LPA receptors and regulate physiological 
responses. For example 18:1 LPA activates all receptors, whereas 20:4 LPA shows a higher 
potency to activate LPA3[37]. Huh-7 cells expressed a range of LPA molecular species and 
HA130 showed differential effects on the genesis of some LPA species. These results 
highlight potential differences in the role of LPA molecular species in the viral life cycle, 
however, this variability may reflect differences in LPC substrate availability and/or lipid 
phosphate phosphatases that may selectively degrade LPA species. 
 
LPA signals through binding to a family of G-protein coupled receptors that can activate 
signalling pathways including PI3 kinase and adenylyl cyclase to induce physiological changes 
including cellular proliferation, anti-apoptosis and migration. Whilst LPA receptor over-
expression studies suggest that individual receptors can regulate physiological responses, 
our understanding of tissue-specific LPA-signalling is limited. PHHs and Huh-7 express all of 
the LPARs at the mRNA level with the exception of LPA4 in Huh-7 cells. The ability of LPA1/3 
antagonist Ki16425[20] to limit HCV infection suggests a direct role for LPA1 or LPA3 in viral 
replication. LPA signalling has been reported to drive chronic wound healing leading to 
fibrosis and LPA modulators are in development for treating fibrosis[38]. A recent study 
reported a role for LPA6 in maintaining the proliferative capacity and tumorigenic phenotype 
of HCC via the transcriptional activation of proto-oncogene Pim-3[39], highlight the value of 
LPA receptor-targeted therapies for treating HCC.  
 
HCC aetiology is multifactorial and the disease is often preceded by other conditions 
including liver fibrosis and cirrhosis that are associated with HCV, HBV, alcoholic and non-
alcoholic hepatitis. The discovery of new therapeutic targets will require a greater 
understanding of the pathogenic mechanisms underlying the tumorigenic process. 
Intrahepatic HCC metastases are common and the tumour microenvironment is considered 
to be pro-metastatic. Reports that elevated serum LPA associate with HCC tumour size and 
patient survival[11], along with resistance to chemotherapy and radiation-induced cell 
death[40], provide compelling evidence to consider the ATX-LPA axis as a therapeutic target 
for treating HCC[41]. The embryonic lethality of ATX null mice[42-44] raised questions on 
the suitability of ATX as a drug target. However, a recent report from Katsifa and colleagues 
showing that inducible, ubiquitous genetic deletion of ATX in adult mice, and long-term 
pharmacologic inhibition were well tolerated limits some of these concerns[45]. In summary, 
we demonstrate a role for ATX-LPA signalling in the HCV lifecycle, highlighting potential new 
targets for therapy and the prospect of stratifying therapies for treating viral-associated and 
non-associated HCC. 
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Figure legends. 
 
Fig.1. HCV induces ATX expression. (a) ATX expression in equal amounts of cellular 
protein or extracellular media from mock or HCV J6/JFH infected Huh-7 cells at 48h post-
infection. Secreted ATX signals were measured by densitometry (annotated on Western 
blots) and expressed relative to the intracellular pool or mock values. Cells were lysed for 
total RNA preparation and ATX and GAPDH mRNA levels measured by real time PCR. (b) ATX 
mRNA levels in mock (n=7) or HCV (n=6) infected uPA-SCID mice transplanted with primary 
human hepatocytes (PHHs), where data is separated according to donor. Serum HCV RNA 
levels at the time of sacrifice varied from 9,300-34,200 IU/mL. ATX mRNA levels are 
expressed relative to uninfected cells (**p<0.01). (c) ATX mRNA levels in uPA-SCID human 
liver chimeric mouse tissue (from 3 PHH donors), short-term cultured PHHs (4 donors) and 
Huh-7 cells expressed relative to GAPDH (**p<0.01). (d) Representative 
immunohistochemical ATX staining in uninfected and HCV infected uPA-SCID liver tissue 
(x400 magnification). All data sets are representative of at least two independent 
experiments. (e) ATX mRNA levels in HCC tumour tissue from patients with underlying HCV 
(n=9), HBV (n=8), ALD (n=8), and normal healthy liver tissues (n=7) (*Mann–Whitney U 
test p<0.05). (f) ATX mRNA levels in HBV-associated HCC tumour and paired non-tumour 
tissue (***Wilcoxon p<0.001). 
 
Fig.2. Low oxygen regulates ATX expression. (a) Huh-7 cells were cultured under 20% 
or 1% oxygen for 24h and analysed for HIF-1 expression; ATX, VEGF and Glut1 mRNA 
levels and secreted ATX (**p<0.01). Huh-7 cells were transfected to express HIF-1 and 
48h later assessed for HIF-1 expression, ATX and VEGF mRNA levels (*p<0.05: **p<0.01). 
ATX protein signals were quantified by densitometry and hypoxic samples expressed relative 
to normoxic ones. (b) Human liver slices from 5 independent donors were incubated under 
20% or 1% oxygen for 24h and total RNA screened for ATX, VEGF and GLUT1 mRNA levels 
(***p<0.001). All gene transcripts are expressed relative to GAPDH housekeeping gene. (c) 
Huh-7 cells expressing ATX promoter-Luc or HRE-Luc were cultured under 20% or 1% 
oxygen for 24h and luciferase activity measured (**p<0.01: ***p<0.001). All data sets are 
representative of at least two independent experiments. (d) Temporal expression of ATX and 
VEGF mRNA levels following HCV infection of Huh-7 cells. Infection was assessed by PCR 
measurement of viral RNA copies at 12, 24 and 48h and were 1.7 x 103, 8.5 x 105 and 4.6 x 
107 RNA copies/105 cells, respectively. (e) Huh-7 cells were transfected with siRNA targeting 
HIF-1 (siHIF) or control (siControl) for 48h, propagated under 1%O2 for 24h to confirm HIF 
silencing by Western blotting or infected with HCV SA13/JFH for 24h and infection assessed 
by enumerating the frequency of NS5A expressing cells.  
 
Fig.3. Association of ATX and hypoxia gene score in HBV-HCC and impact on tumor 
progression. (a) Hypoxia seven-gene signature in HBV-associates HCC tumour and paired 
non-tumour tissues (N=233,Wilcoxon p<0.001). (b) Correlation of relative ATX difference 
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between tumour and paired non-tumour tissues and hypoxia seven-gene signature in HBV-
associated HCC (Pearson correlation coefficient r =0.2788,p<0.0001). (c) Kaplan-Meier 
survival curves of patients classified by high or low ATX expression between tumour and 
paired non-tumour tissues (log-rank test,p=0.198). 
 
Fig.4. Autotaxin promotes HCV infection. For all experiments Huh-7 cells were cultured 
under serum-free conditions for 8h prior to experimentation. (a) Huh-7 cells were treated 
with HA130 (100nM) for 24h, LPA expression and cell viability (MTT) measured (*p<0.05). 
(b) Huh-7 were treated with HA130 for 1h prior to infecting with HCV J6/JFH or SA13/JFH for 
24h (*p<0.05: ***p<0.001). (c) ATX mRNA/protein expression and HCV infection of shATX 
and Control silenced Huh-7 cells (***p<0.001). (d) Control and ATX-silenced Huh-7 cells 
were transfected with plasmids expressing ATX-wt or ATX-T210A and 48h later ATX secretion 
assessed by western blot and cells infected with HCV for 24h (*p<0.05: **p<0.01). (e) 
Control or ATX-silenced Huh-7 cells were treated with HA130 (100nM, 1h) or LPA (10uM, 
15min) prior to infecting with HCV for 24h (*p<0.05: **p<0.01: ***p<0.001). (f) Liver 
specific differentiation markers (albumin, CYP3A4 and HNF4-) and ATX mRNA levels were 
measured in untreated and DMSO differentiated growth-arrested Huh-7 cells (***p<0.001). 
Differentiated cells were incubated with HA130 (100nM) for 1h prior to infecting with HCV 
SA13/JFH. Infectivity was quantified by measuring the frequency of NS5A expressing cells 
and expressed relative to untreated cells (***p<0.001). All data sets are representative of at 
least two independent experiments. Results in (a) show the mean value ± 1 standard error 
of the mean (SEM), where the P values were obtained using two-way ANOVA accounting for 
experimental variability on IBM SPSS Statistics Version 22.  
 
Fig.5. LPA regulates HCV infection. Huh-7 cells were cultured under serum-free 
conditions for 8h and (a) treated with LPA for 15mins prior to infecting with HCV J6/JFH or 
SA13/JFH for 24h (*,p<0.05: ***,p<0.001) or (b) incubated with Ki16425 (10uM) for 
30mins prior to infecting with HCV J6/JFH or SA13/JFH (*p<0.05: **p<0.01: ***p<0.001). 
Infectivity is expressed relative to the untreated samples and represents the mean of three 
replicate infections. Infectivity data is representative of two independent experiments. (c) 
LPAR mRNA expression levels in PHH (4 donors) and Huh-7 cells expressed relative to 
GAPDH.  
 
Fig.6. ATX-LPA signalling regulates HCV RNA replication. For all experiments Huh-7 
cells were cultured under serum-free conditions for 8h prior to experimentation. (a) Huh-7 
cells were incubated with HA130 (100nM) for 1h prior to infecting with HCVpp expressing 
strain H77 or 1A38 envelope glycoproteins for 24h. Infectivity is expressed relative to 
untreated cells and represents the mean of three replicate infections. (b) Huh-7 cells stably 
expressing the Luc2A-JFH replicon were treated with HA130 (100nM) or transduced to 
express shControl or shATX for 24h, cells lysed and luciferase activity measured. Data is 
expressed relative to untreated and represents the mean of three replicate infections 
(***p<0.001). (c) Huh-7 cells were transfected with HCV J6/JFH or a polymerase replication 
defective genome (GND-) that encodes gaussia luciferase (GLuc) and the cells grown under 
serum-free conditions for 8h prior to treating with HA130 (100nM). Extracellular media was 
collected at 0 and 24h post HA130 treatment and luciferase activity measured 
(***p<0.001). Viral replication is assessed by determining the ratio of J6/JFH/GND- 
luciferase activity and represents the mean of three replicate infections. 
 
Fig.7. LPA stabilizes HIF-1 via a PI3K dependent pathway. For all experiments Huh-7 
cells were cultured under serum-free conditions for 8h prior to experimentation. (a) Huh-7 
cells expressing HRE-luciferase reporter were treated with LPA (10µM) in the presence or 
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absence of LPA receptor antagonist Ki16425 (10µM) for 24h. HIF-1 expression was 
measured by Western blotting (***p <0.001). (b) Huh-7 expressing HRE-luciferase reporter 
were treated with NSC-134754 and cultured under normoxia or 1% oxygen for 24h, lysed 
and HIF-transcriptional reporter activity measured (relative light units, RLU). Huh-7 cells 
were treated with 10uM LPA (10µM) in the presence or absence of a sub-saturating dose of 
NSC-134754 (25nM) for 15mins prior to infecting with HCV SA13/JFH for 24h and infectivity 
assessed by enumerating NS5A expressing cells. (c) Huh-7 cells were treated with LPA 
(10uM) and cell lysates (40g) probed for phospho-AKT (pAKT) or total AKT (AKT). (d) Huh-7 
cells were treated with LPA (10M) in the presence of absence of Ki16425 (10M), 
wortmannin (WM) (200nM), BYL-779 (2M) or TGX-221 (50nM) for 24h and cell lysates 
(40g) probed for HIF-1. (e) Huh-7 cells were treated with WM (200nM), BYL-779 (2M) or 
TGX-221 (50nM) for 15mins prior to infection with HCV J6/JFH in the presence or absence of 
LPA (10M). Infectivity is expressed relative to untreated cells and represents the mean of 
three replicate infections (***p<0.001). HCV infection was measured by enumerating the 
frequency of NS5A expressing cells 24h post inoculation (***p<0.001). (f) Schematic model 
of ATX-LPA signaling axis in HCV replicative life cycle.  
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Materials and Methods  
 
Cell lines, antibodies and reagents. Huh-7 (provided by Charles Rice, The Rockefeller 
University, NY, USA) and 293T (American Type Culture Collection) cells were propagated in 
Dulbecco’s modified Eagle Medium (DMEM) supplemented with 10% FBS and 1% non-
essential amino acids (Invitrogen, CA). Huh-7 Luc2a-JFH cells (provided by Robert Thimme, 
Freiburg)[21] were propagated in the same media supplemented with G418. All cells were 
grown at 37°C in 5% CO2. For hypoxic conditions cells were cultured at 37C in a humidified 
sealed H35 Hypoxystation (Don Wiley Scientific, UK) set to 5% CO2/95% N2/1% O2. 
 
The primary antibodies were: anti-NS5A 9E10 (C. Rice, Rockefeller University, USA); anti-
ATX 4FAB; anti-AKT and anti-pAKT (Cell Signaling); anti-HIF-1 (BD Biosciences, Europe). 
Secondary labelled antibodies: Alexa Fluor 488 goat anti-mouse IgG (Invitrogen, CA); 
Horseradish peroxidase conjugated sheep anti-mouse and donkey anti-rabbit (GE Healthcare, 
UK) and anti-rat secondary antibodies (Jackson laboratories). Agonists, inhibitors and 
antagonists were obtained from the following sources: HA130 (Echelon Biosciences), LPA 
(Oleoyl-L-alpha-lysophosphatidic acid sodium salt) and wortmannin (Sigma), Ki16425 
(Cayman Chemical), BYL-719 (Active Biochem) and TGX-221 (Cayman Chemicals). Cell 
lysates were quantifed for protein content using a standard Bradford assay and 40g of 
protein analysed. For quantitation of secreted ATX, 50ul of extracellular serum-free 
conditioned media harvested from a defined cell number was analysed.    
 
Solvents and chemicals for lipids analysis were purchased from the following suppliers: 13:0 
LPA (1-tridecanoyl-sn-glycero-3-phosphate in methanol, Avanti Polar lipids-Stratech 
Scientific Limited), butanol Chromasolv Plus for HPLC and ammonium formate for mass 
spectrometry (Sigma), acetonitrile and water ultra-gradient grade (Romil), formic acid 
Optima LC/MS grade (Fisher Scientific). 
 
uPA-SCID mice infection and immunohistochemical ATX staining. uPA/SCID-bg mice 
were transplanted with PHHs at 3 weeks of age by intrasplenic injection as described[14]. 
Engraftment was assessed by measuring human serum albumin and inoculated with HCV 
J6/JFH (Jc1) virus.  Mice were sacrificed at 16 weeks, the liver recovered and frozen for RNA 
extraction. Liver samples were fixed in formalin for immunostaining purposes. Experiments 
were performed at Inserm Unit 1110 animal facility according to local laws and approved by 
the ethical committee of Strasbourg (number AL/02/19/08/12 and AL/01/18/08/12). 
Sections (3m) of formalin fixed paraffin-embedded liver tissue were deparaffinised, 
rehydrated and after a low temperature retrieval technique and immunostained for ATX using 
a Dako Autostainer. Bound antibody was detected with rabbit anti-rat secondary for 15mins, 
ImmPRESS rabbit secondary for 30mins and visualised using ImmPACT DAB (Vector Labs, 
UK) and counterstained with Meyers haematoxylin. 
 
RT-PCR quantification of ATX and HIF-target genes. Gene amplification was performed 
in a single tube RT-PCR in accordance with manufacturer’s guidelines (CellsDirect kit, 
Invitrogen, CA) and fluorescence monitored in a 7900HT real time PCR machine (ABI, CA). 
The housekeeping gene GAPDH was included as an internal control for amplification 
efficiency and RNA quantification (primer-limited endogenous control, ABI). 
 
HCC liver samples, clinical data and gene expression data. We used an Affymetrix 
U133A2.0 gene expression data set derived from 247 HCC patients as described[16] 
(GSE14520). Patient samples were obtained with informed consent from patients at the Liver 
Cancer Institute and Zhongshan Hospital (Fudan University, Shanghai, China). This cohort 
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contained paired tumour and adjacent non-tumour samples from 232 patients. We also 
performed gene expression analysis of a German cohort from Heidelberg University 
Hospital[15]. These tissues included tumour tissue of HCC patients with underlying alcoholic 
liver disease (ALD, N=8) and HBV (N=8) or HCV (N=9) infection and normal liver samples of 
patients without HCC or liver cirrhosis (NL, N=7). 
 
Ex vivo liver slices. Liver tissue was obtained from patients undergoing resection or 
transplantation surgery at the Queen Elizabeth Hospital, Birmingham. All liver samples were 
collected with local National Health Service research ethics committee approval (Walsall LREC 
04/Q2708/40) and written informed consent. Cores were cut from the tissue immediately 
upon receipt in the laboratory. A Krumdieck Tissue Slicer (Alabama Research and 
Development, USA) was used to section the liver cores. Briefly, the core was placed into the 
slicer under aseptic conditions and circular slices of ~240m thickness generated. Slices 
were immediately transferred into Williams E media (Sigma, UK) supplemented with 1% L-
glutamine and 0.5uM insulin. 
 
Autotaxin promoter activity. Forward (5’CCGGTACCTGTGCTGCGGAAGAAAAGATG3’) and 
reverse (5’GCCTCGAGGAAAGCCTTTAGCGTG3’) primers were used to amplify the ATX 
promoter region from HepG2 genomic DNA. PCR fragments were cloned into luciferase 
reporter plasmid pGL4.28 (Promega, Madison, WI) digested with KpnI and XhoI 
(pGL4.ATX.luc). Huh-7 cells were transfected with pGL4.ATX.luc or pHRE-Luc and 24h later 
re-seeded in 96 well plates and incubated under 20% O2 or 1% O2 for 24h (Don Whitley 
Scientific Limited).  Cells were lysed and luminescence measured. 
 
Mass spectrometric LPA analysis. Huh-7 cells were serum starved for 8h and 
supernatants harvested, clarified and spiked with 1 ng of 13:0 LPA as an internal standard 
prior to extraction with 500 ul of butanol. The combined butanol layers were dried under 
reduced pressure and re-suspended in 100 μl of chloroform/methanol/water 2:5:1 (v/v/v). 5 
μl of each sample was analyzed using a Shimadzu Prominence HPLC connected to a QTrap 
equipped with an electrospray ionisation source (AB Sciex 6500). Separation of LPA species 
from other interfering lipids such as LPS and LPC was achieved using a Cogent Diamond 
Hydride column (1 x 150 mm, 4 μm, Microsolv) with the following conditions: 0.2 ml/min 
flow rate, column temperature 40 oC, autosampler temperature 21 oC. Solvent A was 5 mM 
ammonium formate aqueous solution pH 3.5 and solvent B was acetonitrile containing 0.1% 
formic acid and 1% of a 200 mM aqueous solution of ammonium formate pH 3.5. Gradient 
elution was as follows: isocratic 100% B for 4 minutes, linear decrease 100-75% B in 1.5 
minutes, isocratic 75% B for 3.5 minutes, sharp step down to 25% B and isocratic 25% B for 
5 minutes (washing step), followed by 10 minutes of re-equilibration with 100% B. The mass 
spectrometer was operated in negative ion mode using multiple reaction monitoring to record 
the following transitions: 367.2  153.0 for 13:0 LPA, 381.2  153.0 for 14:0 LPA, 409.2  
153.0 for 16:0 LPA, 437.3  153.0 for 18:0 LPA, 435.3  153.0 for 18:1 LPA, 433.2  
153.0 for 18:2 LPA, 457.2  153.0 for 20:4 LPA, 481.2  153.0 for 22:6 LPA. The following 
optimized MS conditions were used for the analysis: Curtain Gas, 20 psi; Collision Activated 
Dissociation, Medium; Ion Spray Voltage, -4500 V; Ion Source Temperature, 400 oC; Ion 
Source Gas 1, 40 psi; Ion Source Gas 2, 30 psi; Declustering Potential, -110 V; Collision 
Energy, -30 eV; Dwell Time, 50 ms. 
 
HCV genesis and quantification of infection. HCV was generated using the Megascript T7 
kit (Ambion, Austin, TX), RNA was transcribed in vitro from full-length genomes and 
electroporated into Huh-7 cells. After 48h cells were serum starved for 8h prior to collecting 
the serum-free media at 72h post infection and storing at -80°C. Pseudoviruses expressing 
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luciferase reporters were generated following transfection of 293T cells with a 1:1 ratio of 
plasmids encoding HIV provirus expressing luciferase and HCV strain 1A38 or H77 E1E2 
envelope gps (HCVpp-1A38, HCVpp-H77) or empty vector (Env-pp). At 24h post transfection 
cells were serum starved and the pseudoparticles harvested 48h post transfection in serum 
free media. 
 
Target cells were seeded at 1.5x104 cells/cm2 and serum starved for 8h prior to infection 
with HCV or HCVpp in serum-free media for 24h. HCV infection was assessed following 
methanol fixation and staining for NS5A with 9E10 antibody; bound antibody was detected 
with an Alexa 488-conjugated anti-mouse IgG and quantified by enumerating NS5A+ cells. 
Pseudoparticle infection was quantified by measuring cellular luciferase activity in a 
luminometer (Berthold Centro LB 960). Relative infectivity was calculated as a percentage of 
untreated cells and presented  standard error of the mean (SEM), where the mean infection 
value of replicate untreated cells wells was defined as 100%.  
 
Assessing the role of ATX in the HCV life cycle. Target cells were seeded at 1.5 x 
104/cm2 and serum starved for 8h prior to infection. Cells were incubated with HA130 
(60min), LPA (in the presence of 0.1mg/ml fatty acid free BSA) (15min), Ki16425 or LPA 
plus Ki16425 (15min) diluted in serum-free media prior to infecting with HCV or HCVpp for 
24h. Huh-7 Luc2a-JFH expressing cells or shATX/shControl transduced cells were seeded at 
1.5 x 104/cm2 and serum starved for 8h prior to assay. Cells were untreated or incubated 
with HA130 for 24h prior to lysis and measuring luciferase. Huh-7 cells were transfected with 
JC1GLuc for 24h, serum starved for 8h and washed extensively before treating with HA130 
for 24h. Extracellular media was harvested, heat inactivated and luciferase activity 
measured.  
 
Autotaxin silencing, rescue, and HIF-1 silencing. 293T cells were transfected with 
plasmids plKO.1 shATX (TRCN0000048993) or plKO.1 control (Open Biosystems) plus p8.2 
gag pol and VSV-G and 72h later lentiviral particles harvested and used to transduce Huh-7. 
Cells were cultured in the presence of puromycin and ATX knockdown determined by 
Western blotting. shControl and shATX stable expressing Huh-7 cells were transfected with 
His-tagged wild type ATX (ATX-wt) or T210A ATX mutant (ATX-T210A) (Addgene plasmid 
17839 and 17840 respectively) for 24h prior to seeding cells for infection studies. Huh-7 cells 
were transfected using Dharmafect according to manufactures instructions with siHIF-1 
(siHIF) or shControl (Thermoscientific, UK) and incubated for 48h prior assessing HIF-1 by 
Western blot or infecting with HCV.  
 
Statistical analysis. Results are shown as the mean value ± 1 standard deviation (SD) 
except where stated otherwise, all data were tested for fit a Gaussian assumptions and 
analyses performed using either Student’s t-test (pairwise comparisons) or Kruskal-Wallis 
One-Way ANOVA with Dunn’s test (for multiple comparisons), except where stated 
otherwise, in Graph Pad Prism 6 (GraphPad, USA), with a P value of <0.05 considered 
statistically significant. Expression differences between HCC and non-tumorous liver samples 
were assessed by Wilcoxon signed-rank test for paired samples. Kaplan-Maier curves and 
log-rank test were performed with Graph Pad Prism 6. Differential expression in aetiology 
groups of the German cohort were analysed by nonparametric Mann-Whitney U tests. The 
hypoxia score was calculated as previously reported[17]. 
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